Literature DB >> 20194700

Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Margaret Okomo-Adhiambo1, Gail J Demmler-Harrison, Varough M Deyde, Tiffany G Sheu, Xiyan Xu, Alexander I Klimov, Larisa V Gubareva.   

Abstract

The clinical use of the neuraminidase inhibitor (NAI) oseltamivir is associated with the emergence of drug resistance resulting from subtype-specific neuraminidase (NA) mutations. The influenza A/Texas/12/2007 (H3N2) virus isolated from an oseltamivir-treated immunocompromised patient exhibited reduced susceptibility to oseltamivir in the chemiluminescent neuraminidase inhibition (NI) assay (approximately 60-fold increase in its 50% inhibitory concentration [IC(50)] compared to that for a control virus). When further propagated in cell culture, the isolate maintained reduced susceptibility to oseltamivir in both chemiluminescent and fluorescent NI assays (approximately 50- and 350-fold increases in IC(50), respectively). Sequencing analysis of the isolate revealed a mix of nucleotides coding for amino acids at position 119 of the NA [E119(V/I)]. Plaque purification of the isolate yielded E119V and E119I variants, both exhibiting reduced susceptibility to oseltamivir. The E119I variant also showed decreased susceptibility to zanamivir and the investigational NAIs peramivir and A-315675. The emergence of E119V variants in oseltamivir-treated patients has been previously reported; however, the E119I mutation detected here is a novel one which reduces susceptibility to several NAIs. Both mutations were not detected in unpropagated original clinical specimens using either conventional sequencing or pyrosequencing, suggesting that these variants were present in very low proportions (<10%) in clinical specimens and gained dominance after virus propagation in MDCK cells. All virus isolates recovered from the patient were resistant to adamantanes. Our findings highlight the potential for emergence and persistence of multidrug-resistant influenza viruses in oseltamivir-treated immunocompromised subjects and also highlight challenges for drug resistance diagnosis due to the genetic instability of the virus population upon propagation in cell culture.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20194700      PMCID: PMC2863645          DOI: 10.1128/AAC.01608-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.

Authors:  Yacine Abed; Mariana Baz; Guy Boivin
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

2.  Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.

Authors:  J M Colacino; W G Laver; G M Air
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

3.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase.

Authors:  P M Colman; J N Varghese; W G Laver
Journal:  Nature       Date:  1983 May 5-11       Impact factor: 49.962

4.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; M J Robinson; R C Bethell; R G Webster
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

Review 5.  Oseltamivir for treatment and prophylaxis of influenza infection.

Authors:  Patricia Schirmer; Mark Holodniy
Journal:  Expert Opin Drug Saf       Date:  2009-05       Impact factor: 4.250

6.  Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

Authors:  L V Gubareva; M N Matrosovich; M K Brenner; R C Bethell; R G Webster
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

7.  Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Authors:  Aeron C Hurt; Jessica K Holien; Michael Parker; Anne Kelso; Ian G Barr
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

8.  Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.

Authors:  Varough M Deyde; Margaret Okomo-Adhiambo; Tiffany G Sheu; Teresa R Wallis; Alicia Fry; Nila Dharan; Alexander I Klimov; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2008-10-07       Impact factor: 5.970

9.  Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Authors:  Margaret Okomo-Adhiambo; Ha T Nguyen; Katrina Sleeman; Tiffany G Sheu; Varough M Deyde; Rebecca J Garten; Xiyan Xu; Michael W Shaw; Alexander I Klimov; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2009-11-13       Impact factor: 5.970

10.  Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs.

Authors:  Clyde Dapat; Yasushi Suzuki; Reiko Saito; Yadanar Kyaw; Yi Yi Myint; Nay Lin; Htun Naing Oo; Khin Yi Oo; Ne Win; Makoto Naito; Go Hasegawa; Isolde C Dapat; Hassan Zaraket; Tatiana Baranovich; Makoto Nishikawa; Takehiko Saito; Hiroshi Suzuki
Journal:  Emerg Infect Dis       Date:  2010-03       Impact factor: 6.883

View more
  43 in total

1.  Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.

Authors:  Rachel R Higgins; Melissa Beniprashad; Eddie Chong-King; Yan Li; Nathalie Bastien; Donald E Low; Jonathan B Gubbay
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.

Authors:  Richard H Beigi; Kelong Han; Raman Venkataramanan; Gary D Hankins; Shannon Clark; Mary F Hebert; Thomas Easterling; Anne Zajicek; Zhaoxia Ren; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2011-03-09       Impact factor: 8.661

3.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

4.  Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.

Authors:  Silvana Carr; Natalia A Ilyushina; John Franks; Elisabeth E Adderson; Miguela Caniza; Elena A Govorkova; Robert G Webster
Journal:  Pediatr Infect Dis J       Date:  2011-04       Impact factor: 2.129

5.  Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Authors:  Daisuke Tamura; Margaret Okomo-Adhiambo; Vasiliy P Mishin; Zhu Guo; Xiyan Xu; Julie Villanueva; Alicia M Fry; James Stevens; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

6.  Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Authors:  Susu Duan; David A Boltz; Jiang Li; Christine M Oshansky; Henju Marjuki; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

7.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

8.  Genetic analysis of H3N2 avian influenza viruses isolated from live poultry markets and poultry slaughterhouses in Shanghai, China in 2013.

Authors:  Dequan Yang; Jian Liu; Houbin Ju; Feifei Ge; Jian Wang; Xin Li; Jinping Zhou; Peihong Liu
Journal:  Virus Genes       Date:  2015-04-22       Impact factor: 2.332

9.  Detection of a transient R292K mutation in influenza A/H3N2 viruses shed for several weeks by an immunocompromised patient.

Authors:  N Esther Babady; Jennifer M Laplante; Yi-Wei Tang; Kirsten St George
Journal:  J Clin Microbiol       Date:  2015-01-14       Impact factor: 5.948

10.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.